| Devin Talmage Whipple, OD | |
|
15465 W Mcdowell Rd Ste 101, Goodyear, AZ 85395-2528 | |
| (623) 247-2706 | |
| Not Available |
| Full Name | Devin Talmage Whipple |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | 15465 W Mcdowell Rd Ste 101, Goodyear, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598317117 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPT-002362 (Arizona) | Primary |
| Provider Name | Independence Corporation |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1972549657 PECOS PAC ID: 0749351005 Enrollment ID: O20080616000088 |
News Archive
Our sense of belonging to the male or female gender is an inherent component of the human identity perception. As a general rule, gender identity and physical sex coincide. If this is not the case, one refers to trans-identity or transsexuality. In a current study, brain researcher Georg S. Kanz of the University Clinic for Psychiatry and Psychotherapy of the MedUni Vienna was able to demonstrate that the very personal gender identity of every human being is reflected and verifiable in the cross-links between brain regions.
Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application for flibanserin earlier this year and expects US Food and Drug Agency action before the end of 2013.
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, announced today that it has entered R-Bambuterol Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.
› Verified 5 days ago
| Provider Name | Conestoga Eye Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1952780520 PECOS PAC ID: 1456669894 Enrollment ID: O20151005000084 |
News Archive
Our sense of belonging to the male or female gender is an inherent component of the human identity perception. As a general rule, gender identity and physical sex coincide. If this is not the case, one refers to trans-identity or transsexuality. In a current study, brain researcher Georg S. Kanz of the University Clinic for Psychiatry and Psychotherapy of the MedUni Vienna was able to demonstrate that the very personal gender identity of every human being is reflected and verifiable in the cross-links between brain regions.
Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application for flibanserin earlier this year and expects US Food and Drug Agency action before the end of 2013.
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, announced today that it has entered R-Bambuterol Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Devin Talmage Whipple, OD 1356 S Gilbert Rd, Ste 3, Mesa, AZ 85204-6077 Ph: (480) 545-8985 | Devin Talmage Whipple, OD 15465 W Mcdowell Rd Ste 101, Goodyear, AZ 85395-2528 Ph: (623) 247-2706 |
News Archive
Our sense of belonging to the male or female gender is an inherent component of the human identity perception. As a general rule, gender identity and physical sex coincide. If this is not the case, one refers to trans-identity or transsexuality. In a current study, brain researcher Georg S. Kanz of the University Clinic for Psychiatry and Psychotherapy of the MedUni Vienna was able to demonstrate that the very personal gender identity of every human being is reflected and verifiable in the cross-links between brain regions.
Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application for flibanserin earlier this year and expects US Food and Drug Agency action before the end of 2013.
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, announced today that it has entered R-Bambuterol Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.
› Verified 5 days ago
Dr. Anna L.o. Moore, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2580 N Litchfield Rd, Goodyear, AZ 85395 Phone: 623-932-2020 Fax: 623-932-2668 | |
Dr. Michael Brayden Lundquist, OD, FAAO, FSLS Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2580 N Litchfield Rd, Goodyear, AZ 85395 Phone: 623-932-2020 | |
Dr. Brent J Wilson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2580 N Litchfield Rd, Goodyear, AZ 85395 Phone: 623-932-2020 Fax: 623-932-2668 | |
Dr. Elesha Rae Starkey, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2580 N Litchfield Rd, Goodyear, AZ 85395 Phone: 617-288-3230 | |
Dr. Mary V Fisher, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1626 N Litchfield Rd Ste 110, Goodyear, AZ 85395 Phone: 602-955-1000 Fax: 602-508-4830 | |
Dr. James Edward Mills, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 14009 W Mcdowell Rd, Goodyear, AZ 85395 Phone: 623-935-9784 | |
Dr. Zakri Marcus Burns, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1100 N Estrella Pkwy, Goodyear, AZ 85338 Phone: 623-925-9971 Fax: 623-925-9982 |